The 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR - "Innovative Diagnostics to Help Manage HSCT Complications Post-Transplant"

Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:

• Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
• Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
• Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

Tailoring CMV Prophylaxis Based on a CMV T Cell Immunity Panel Assay in Kidney Transplant Patients

Presented By:
Dr. Clifford Miles, MD, FAST
Associate Professor
Internal Medicine-Nephrology
University of Nebraska Medical Center
Medical Director, Kidney & Pancreas Transplantation, Nebraska Medicine

This interesting presentation will review The University of Nebraska's Kidney Transplant program's strategy of using CMV inSIGHT T Cell Immunity testing to serially monitor high risk kidney transplant patients to evaluate if prophylaxis could be discontinued early. Dr. Clifford Miles will review data originally presented at the Cutting Edge of Transplantation earlier this year. Dr. Miles is the Medical Director of Kidney and Pancreas Transplant at the University of Nebraska's Medical Center and Associate Professor, Nephrology Division at UNMC's college of medicine. 

Including a special Q&A between authors of the study.